Research programme: small molecule therapeutics - Elorac

Drug Profile

Research programme: small molecule therapeutics - Elorac

Alternative Names: Small molecules Heprotect™

Latest Information Update: 03 Mar 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Gideon Pharmaceuticals
  • Developer Elorac
  • Class
  • Mechanism of Action 14-alpha demethylase inhibitors; Cyclo-oxygenase 2 inhibitors; Retinoic acid receptor agonists; Tetrahydrofolate dehydrogenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer; Inflammation; Mycoses; Pain; Psoriasis

Most Recent Events

  • 19 Jan 2017 Preclinical trials in Inflammation in USA
  • 19 Jan 2017 USPTO Issues Patent To Elorac for treating chronic inflammatory diseases
  • 15 Apr 2016 Preclinical trials in Psoriasis, Mycoses, Pain, Psoriasis in USA (unspecified route) before April 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top